Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias

被引:17
|
作者
Albers, Max B. [1 ,2 ,3 ]
Almquist, Martin [1 ,2 ]
Bergenfelz, Anders [1 ,2 ]
Nordenstrom, Erik [1 ,2 ]
机构
[1] Lund Univ, Skane Univ Hosp, Dept Surg, Lund, Sweden
[2] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Lund, Sweden
[3] Philipps Univ Marburg, Dept Visceral Thorac & Vasc Surg, Marburg, Germany
关键词
Neuroendocrine neoplasia; Perioperative complications; Surgery; Gastro-entero-pancreatic system; Small intestine; Pancreas; ENETS CONSENSUS GUIDELINES; POSTOPERATIVE COMPLICATIONS; TUMORS; MANAGEMENT; UPDATE; RESECTION; CLASSIFICATION; MORTALITY; PROPOSAL; OUTCOMES;
D O I
10.1007/s00423-020-01869-0
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose Surgery is recommended for most patients with gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NENs). Rates of complications and perioperative mortality have been reported in few mostly retrospective single-center series, but there has been no detailed analysis on risk factors for perioperative complications and mortality to date. Methods Data of patients with GEP-NENs operated between January 2015 and September 2018 were retrieved from EUROCRINE (c), a European online endocrine surgical quality registry, and analyzed regarding rate and risk factors of surgical complications. Risk factors were assessed by logistic regression. Results Some 376 patients (211 female, 167 male; age median 63, range 15-89 years) were included. Most NENs were located in the small intestine (SI) (n = 132) or pancreas (n = 111), the rest in the stomach (n = 34), duodenum (n = 30), appendix (n = 30), colon, and rectum (n = 22), or with unknown primary (n = 15). Of the tumors, 320 (85.1%) were well or moderately differentiated, and 147 (39.1%) of the patients had distant metastases at the time of operation. Severe complications (Dindo-Clavien >= 3) occurred in 56 (14.9%) patients, and 4 (1.1%) patients died perioperatively. Severe complications were more frequent in surgery for duodenopancreatic NENs (n = 31; 22.0%) compared with SI-NENs (n = 15; 11.4%) (p = 0.014), in patients with lymph node metastases operated with curative aim of surgery (n = 24; 21.4%) versus non-metastasized tumors or palliative surgery (n = 32; 12.1%) (p = 0.020), and in functioning tumors (n = 20; 23.0%) versus non-functioning tumors (n = 30; 13.5%) (p = 0.042). Complication rates were not significantly associated with tumor stage or grade. Conclusions Severe complications are frequent in GEP-NEN surgery. Besides duodenopancreatic tumor location, curative resection of nodal metastases and functioning tumors are risk factors for complications.
引用
收藏
页码:137 / 143
页数:7
相关论文
共 50 条
  • [1] Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias
    Max B. Albers
    Martin Almquist
    Anders Bergenfelz
    Erik Nordenström
    Langenbeck's Archives of Surgery, 2020, 405 : 137 - 143
  • [2] Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract
    Goretzki, Peter E.
    Mogl, Martina T.
    Akca, Aycan
    Pratschke, Johann
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2018, 19 (02): : 169 - 178
  • [3] Classification of gastro-entero-pancreatic neuroendocrine tumors
    Perren, A.
    Schmitt, A.
    Komminoth, P.
    Pavel, M.
    RADIOLOGE, 2009, 49 (03): : 198 - 205
  • [4] Differentiated Strategies for the Therapy of Liver Metastases in Gastro-entero-pancreatic Neuroendocrine Neoplasia
    Mogl, Martina T.
    Oellinger, Robert
    Jann, Henning
    Gebauer, Bernhard
    Fehrenbach, Uli
    Amthauer, Holger
    Wetz, Christoph
    Schmelzle, Moritz
    Raschzok, Nathanael
    Krenzien, Felix
    Goretzki, Peter E.
    Pratschke, Johann
    Schoening, Wenzel
    ZENTRALBLATT FUR CHIRURGIE, 2022, 147 (03): : 270 - 280
  • [5] Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract
    Peter E. Goretzki
    Martina T. Mogl
    Aycan Akca
    Johann Pratschke
    Reviews in Endocrine and Metabolic Disorders, 2018, 19 : 169 - 178
  • [6] Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?
    Fottner, Christian
    Ferrata, Martina
    Weber, Matthias M.
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2017, 18 (04): : 393 - 410
  • [7] Surgical management of gastro-entero-pancreatic neuroendocrine tumours
    Arkuszewski, Piotr
    Pasieka, Zbigniew
    Kolomecki, Krzysztof
    Smigielski, Jacek
    Kusinski, Michat
    Hedayati, Masoud
    Srebrzynski, Adam
    Kuzdak, Krzysztof
    PRZEGLAD GASTROENTEROLOGICZNY, 2011, 6 (04): : 252 - 258
  • [8] Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options
    Merola, Elettra
    Prasad, Vikas
    Pascher, Andreas
    Pape, Ulrich-Frank
    Arsenic, Ruza
    Denecke, Timm
    Fehrenbach, Uli
    Wiedenmann, Bertram
    Pavel, Marianne Ellen
    NEUROENDOCRINOLOGY, 2020, 110 (06) : 517 - 524
  • [9] Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma
    Li, Mu-Xing
    Lopez-Aguiar, Alexandra G.
    Poultsides, George
    Rocha, Flavio
    Weber, Sharon
    Fields, Ryan
    Idrees, Kamran
    Cho, Cliff
    Maithel, Shishir K.
    Zhang, Xu-Feng
    Pawlik, Timothy M.
    JOURNAL OF SURGICAL ONCOLOGY, 2022, 126 (04) : 689 - 697
  • [10] GEP-NETS UPDATE A review on surgery of gastro-entero-pancreatic neuroendocrine tumors
    Partelli, Stefano
    Maurizi, Angela
    Tamburrino, Domenico
    Baldoni, Andrea
    Polenta, Vanessa
    Crippa, Stefano
    Falconi, Massimo
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2014, 171 (04) : R153 - R162